Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,556
  • Shares Outstanding, K 7,003
  • Annual Sales, $ 59,030 K
  • Annual Income, $ -4,370 K
  • 60-Month Beta 1.46
  • Price/Sales 0.65
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALIM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.61
  • Number of Estimates 1
  • High Estimate -0.61
  • Low Estimate -0.61
  • Prior Year 0.76
  • Growth Rate Est. (year over year) -180.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.67 +11.98%
on 06/14/22
6.50 -19.55%
on 06/09/22
-0.92 (-14.97%)
since 06/06/22
3-Month
3.94 +32.72%
on 05/12/22
6.50 -19.55%
on 06/09/22
-0.33 (-5.95%)
since 04/06/22
52-Week
3.94 +32.72%
on 05/12/22
9.79 -46.59%
on 08/13/21
-3.79 (-42.03%)
since 07/06/21

Most Recent Stories

More News
Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant

ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...

ALIM : 5.26 (+0.77%)
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choice...

ALIM : 5.26 (+0.77%)
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ALIM : 5.26 (+0.77%)
ANIP : 31.89 (-0.19%)
Alimera Sciences Reports First Quarter 2022 Results

Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021U.S. Net Revenue Increased 23% vs. First Quarter of 2021U.S. End User Demand Up...

ALIM : 5.26 (+0.77%)
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update

Conference Call to be held the same day at 9:00am Eastern Time...

ALIM : 5.26 (+0.77%)
Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OCGN : 2.57 (-1.15%)
ALIM : 5.26 (+0.77%)
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 23.92 (-3.35%)
ALIM : 5.26 (+0.77%)
Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress

Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research in Vision and Ophthalmology (ARVO) conference...

ALIM : 5.26 (+0.77%)
New Strong Sell Stocks for April 26th

ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022

ALIM : 5.26 (+0.77%)
ANIK : 22.50 (-1.10%)
ADAP : 1.7300 (+4.22%)
Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation

ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...

ALIM : 5.26 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

3rd Resistance Point 6.04
2nd Resistance Point 5.72
1st Resistance Point 5.47
Last Price 5.26
1st Support Level 4.90
2nd Support Level 4.58
3rd Support Level 4.33

See More

52-Week High 9.79
Fibonacci 61.8% 7.56
Fibonacci 50% 6.86
Fibonacci 38.2% 6.17
Last Price 5.26
52-Week Low 3.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar